YouthBio Therapeutics (YouthBio), a pioneering longevity biotechnology company developing partial reprogramming-based gene therapies, today announced significant research results from its collaboration with Dr.
As several gene therapy approvals for rare disease treatment gain steam in 2023, a comprehensive set of gene therapy development solutions is released to pave richer avenues for rare disease research.
Neuronity Therapeutics, Inc., a pioneering biotech company focused on neurodegenerative diseases, is delighted to announce the receipt of a $780k grant in collaboration with the University of Georgia (UGA) from The Michael J. Fox Foundation (MJFF).
